FOXO Technologies Inc. Delisted from NYSE, Begins Trading on OTC
On August 13, 2025, FOXO Technologies Inc., a software company specializing in underwriting protocol and consumer engagement platforms based on epigenetic technology, announced its delisting from the NYSE American. The company’s Class A common stock, which had been trading under the ticker symbol FOXO, was suspended from trading on August 12, 2025, after its share price fell below the NYSE’s minimum requirement of $0.10.
The delisting was confirmed by a letter from NYSE on August 12, 2025, stating that NYSE Regulation had initiated proceedings to delist the stock pursuant to Section 1003(f)(v) of the NYSE American Company Guide. As a result, FOXO Technologies Inc. has transitioned to trading on the Over-the-Counter (OTC) market, effective August 13, 2025. The company received confirmation from FINRA’s Department of Market Operations that its common stock could be quoted and traded on the OTC market under the same trading symbol, “FOXO.”
Despite the delisting, FOXO Technologies Inc. remains committed to its business strategy and economic outlook. Seamus Lagan, Chief Executive Officer of FOXO, expressed that while the company is disappointed by the delisting, it does not alter their strategic direction. The company continues to focus on its current business operations and is actively pursuing acquisitions to accelerate growth. Additionally, FOXO is considering future listings on NYSE or NASDAQ when appropriate.
As of August 11, 2025, FOXO Technologies Inc. had a close price of $0.092, with a 52-week high of $25.8964 and a low of $0.086. The company’s market capitalization stands at approximately $931,273 USD. Operating globally, FOXO serves insurers, health researchers, and life science companies, leveraging its expertise in epigenetic technology to enhance consumer engagement and underwriting processes.